Background: We evaluated the long-term results of radiotherapy for patients with gastric marginal zone lymphoma (GMZL).
introduction
The management of gastric marginal zone lymphoma (GMZL) has evolved in recent decades reflecting greater knowledge of its aetiology and clinical behaviour [1] [2] [3] [4] [5] . The eradication of Helicobacter pylori (HP) infection is effective treatment for most patients with GMZL. However, ∼20% of patients do not achieve a complete response (CR) despite anti-Helicobacter therapy and relapse among responders occurs in a similar percentage of cases. Therapeutic options after failure of HP eradication (HPE) include observation, surgery, chemotherapy, monoclonal antibody treatment and radiotherapy [4, [6] [7] [8] [9] [10] [11] [12] [13] [14] . Radiotherapy is an effective therapy for localized MZL in several extra-nodal sites including stomach [7, [9] [10] [11] [12] [13] [15] [16] [17] . In order to evaluate the long-term outcome and prognostic factors following radiotherapy for GMZL, we carried out a retrospective analysis on a large, multi-centre patient cohort with long-term follow-up, under the auspices of the International Extranodal Lymphoma Study Group (IELSG). methods Eligible patients had a histological diagnosis of GMZL localized to stomach ± regional lymph nodes and received curative-intent radiotherapy between 17 July 1981 and 25 March 2004 . Patients were excluded if they had a prior lymphoma history or were in CR from previous therapy for GMZL before commencement of radiotherapy. Eligible patients had progressive disease or persistent disease at least 6 months following prior HPE or evidence of disease following chemotherapy or surgery (including positive surgical margins). Patient, tumour, treatment and outcome data were recorded on purpose-designed case record forms (CRFs). When data were incomplete, descriptive data are provided for the subset of patients for whom the relevant data were available.
Histological classification was based on reports at the time of treatment. The growth pattern (uni/multi-focal, exophytic/tumour-like, stomach wall thickening based on computed tomography (CT) or endoscopic ultrasound) was recorded. Patients were classified as having low-grade GMZL, or low-grade GMZL with a large-cell component, when a large-cell element was described in the histopathology report but considered insufficient to classify as diffuse large B-cell lymphoma (DLBCL). Central pathology review was not part of the present study, but most cases were treated at academic centres, and most cases in the Dutch cohort underwent formal pathology review. The Lugano staging system was used: stage I (lymphoma confined to the stomach); II 1 (stomach and regional lymph nodes) or II 2 (stomach and distant abdominal lymph nodes) [18] .
The gastroscopic response following radiotherapy was recorded and patients were followed according to institutional practice. Treatment failure was defined as persistent disease or recurrent lymphoma after CR. Failure in the stomach/regional nodes was classified as loco-regional failure and relapse at other sites as distant failure. Dates and sites of second malignancies were recorded. Some patients in this study formed part of previously published series [10, 14, 19] . The study was conducted in accordance with the institutional review board requirements of all participating centres and conducted under the auspices of the IELSG.
statistical analysis
Descriptive statistics on baseline patient characteristics, previous therapy and radiotherapy treatment are presented. Where descriptive data were missing for some patients, they are reported as a percentage of the patients for whom data were available. The proportion of all patients achieving a CR after commencing radiotherapy was computed together with the 95% confidence interval (CI), calculated using the Blyth-Still-Casella method. No close-out date was employed for the time-to-event analyses because of the wide range in dates of the last follow-up. The median patient follow-up was estimated using the reverse Kaplan-Meier method [20] . Overall survival (OS), freedom from treatment failure (FFTF) and freedom-from local treatment failure (FFLTF) were defined as the time from commencement of radiotherapy to the date of death from any cause, the date of documented residual or recurrent disease or the date of documented residual or recurrent local disease, respectively. Death was considered a censoring event for FFTF and FFLTF. In the subset of 42 patients with a recorded date of follow-up endoscopy, endoscopic FFTF was calculated. This was the time to any treatment failure censored at the date of last gastroscopy, unless failure was documented after the last gastroscopy. These end points were estimated using the Kaplan-Meier product limit method. The 95% CIs for the proportion of patients surviving without experiencing the relevant event at particular times was estimated using the logit transformation. Statistical analyses were carried out using R2.15.0 software [21] . A prognostic factor analysis included age, sex, failure of prior therapy, presence of large-cell component, multi-focal disease, exophytic disease, stage and radiotherapy dose and volume (whole abdominal or not). Stomach wall thickening was assessed by CT or endoscopic ultrasound at different centres and the prognostic impact of wall thickening evaluated by each method was analysed separately. The incidence of late renal impairment and second malignancy was estimated.
results
Of 143 cases evaluated, 41 were excluded: 2 had distant disease at presentation, 18 had prior gastrectomy with clear/unknown pathological margins, 16 had HPE with an interval of <6 months and no definite tumour progression before radiotherapy and 5 had a CR to chemotherapy without subsequent progression. This left 102 eligible patients for analysis. Patient characteristics before radiotherapy are shown in Table 1 .
Evidence of HP infection was identified in 55 of 90 cases (61%). In 13 of 101 cases (13%), a large-cell element was noted 
treatment before radiotherapy
Prior therapy had been given in 44 patients (43%): HPE in 29 patients; surgery in 5; chemotherapy in 3; HPE and chemotherapy in 4; surgery and chemotherapy in 1; HPE and surgery in 1 and 1 had all three modalities. Chemotherapy regimens were chlorambucil-based (n = 5); cyclophosphamide, doxorubicin, vincristine and prednisolone (n = 3); and cyclophosphamide, vincristine and prednisolone (n = 1). All 35 patients who received HPE had evidence of persistent lymphoma before receiving radiotherapy. The median interval from HPE to radiotherapy was 15 months (range 2-44 months). In 28 patients, persistent disease was reported ≥6 months following HPE. Of the remaining seven cases, five were HP-negative at diagnosis and two were HP-postive but had progressive disease after HPE. All but one patient had symptoms before radiotherapy, including bleeding in four and weight-loss in two. Four of nine patients who had chemotherapy failed to achieve a CR and five relapsed after a CR. Of eight patients who had surgery, five had positive margins and three with negative margins relapsed locally following surgery.
radiotherapy
The median age at commencement of radiotherapy was 63 (range 22-85) years. Disease-related symptoms before radiotherapy were noted in 66 patients including bleeding in 26 and weight-loss in 18 patients. All patients underwent curative-intent radiotherapy. The median total radiation dose was 40 Gy (range 26-46 Gy) in a median of 22 fractions over a median duration of 28 days. Nineteen patients received ≤30.6 Gy, 30 received 31-39 Gy and 53 received ≥40 Gy. Radiation fields encompassed the stomach and involved nodes in 61 patients and 41 had whole abdominal radiotherapy (median dose 20 Gy, range 14-27 Gy) followed by gastric boost. The radiotherapy technique was described as an antero-posterior pair in 20 cases, a multi-field technique in 20 cases and was not stated in the remainder.
outcome following radiotherapy
Following radiotherapy, 98 patients (96%) were classified as having a CR, in 97 cases based on post-radiotherapy gastroscopy, and in one case without gastroscopy documented. Four patients were categorized as response unknown, but in all four cases, subsequent gastroscopies did not show evidence of disease in the absence of any additional post-radiotherapy treatment. At a median follow-up of 7.9 years (range 0.3-24 years), the 10-and 15-year FFTF was estimated at 88% (95% CI 82% to 95%) ( Fig. 1A) . The 10-year FFLTF rate was 93% (95% CI 87% to 98%). As some patients were followed clinically beyond the last recorded date of gastroscopy, an additional analysis was carried out on 40 patients censoring at the date of last recorded gastroscopy. In this analysis, the 10-year FFTF was 87% (95% CI 75% to 100%). Several potential prognostic factors for FFTF were evaluated on univariate analysis, as incomplete data and the small number of events precluded a formal multivariate analysis ( Table 2 ). The significant factors were the presence of a large-cell component [hazard ratio (HR) 4.1, P = 0.036] and exophytic disease (HR 5.4, P = 0.04). Neither radiotherapy dose nor volume (whole versus partial abdominal) was a significant prognostic factor, and patients receiving <30.6 Gy had a similar FFTF rate to patients receiving ≥40 Gy. There were 11 instances of treatment failure after radiotherapy: 3 patients had persistent disease following radiotherapy, and 8 patients relapsed. Sites of relapse were stomach only in two, stomach/regional nodes in one, stomach and distant site in one and distant sites only in four (bone marrow three, supra-diaphragmatic nodes in two and lung in one-some had more than one site). The characteristics of patients with treatment failure after radiotherapy are summarized in Table 3 . Subsequent management of these 11 patients included surgery in 2, chemotherapy in 4, and 5 were observed. Six of these 11 patients have died due to: three MZL, one abdominal aortic aneurysm and two unknown cause.
Thirteen second malignancies were recorded (6 males, 7 females, median age 58 years, range 45-82 years): lung 2, colon 2, prostate 2, other pelvic malignancy 2, breast 2, basal cell carcinoma of skin 1, other skin cancer 1, larynx 1. Second malignancies were observed in 8 of 56 patients who received WAR, of which 3 were likely in field (2 prostate and 1 endometrium), 2 were out of field (1 larynx and 1 skin of neck) and 3 had uncertain relationship to the field (1 breast, 1 lung and 1 skin unknown site). Second malignancies were reported in 5 of 41 patients who had gastric/nodal irradiation only, of which 2 were likely in-field (2 colon), 1 was likely out of field (bladder) and 2 had uncertain relationship to field (1 breast, 1 lung). The actuarial incidence of second malignancy was 14% at 10 years and 20% at 20 years. No late renal failure was recorded. At last follow-up, 31 patients were deceased, 65 patients were alive without evidence of MZL, 2 patients were alive with MZL, 3 were alive with MZL status unknown and 1 had vital status unknown. The 10-year OS rate was estimated at 70% (95% CI 60% to 82%) ( Fig. 1B) . Causes of death were MZL 3, other malignancy 11, cardiovascular 8, infection 2, and other/unknown 7.
discussion
In this retrospective, multi-centre study, patients treated with radiotherapy for GMZL had a 10-and 15-year FFTF rate of 88%. These data support and extend the results of previous studies of radiotherapy for GMZL (Table 4) [31] . Prognostic factors for patients treated with radiotherapy are less well characterized. We reported that a large-cell component was associated with a poorer outcome, in keeping with previous reports [17, 31] . We also observed that exophytic disease was associated with an adverse outcome after radiotherapy, and that there was a trend to poorer outcome with increasing age, lymph node involvement and stomach wall thickening. This raises questions about the suitability of treatment with radiotherapy alone in the presence of these risk factors. As distant failure was seen in <5% of cases, it is unlikely that more sensitive and extensive systemic staging (e.g. routine PET scanning) will substantially improve outcomes [32] . Our series differs in several key respects from previous studies of GMZL. In the three largest reported series, almost all patients received whole abdominal radiation, with the total doses of 40 Gy to the stomach [10, 22, 33] . In the present study, 61 cases received local radiotherapy only, and 19 received <30.6 Gy, allowing an exploration of the effect of both field-size and dose on outcome. Patients were included in the present analysis only if they received radiotherapy for active disease, rather than in a potentially 'adjuvant' role. Patients who had prior therapy were excluded unless they had progressive or persistent disease ≥6 months after prior HPE, and they were required to have evidence of disease after prior chemotherapy or surgery. In contrast, not all previous studies used defined criteria for failure of HPE before radiotherapy [22, 33] . A further strength of this study is the long median follow-up of 95 months, compared with 32-77 months in previous reports. The present study is subject to several limitations common to retrospective studies. Determining selection criteria for specific forms of treatment, and the application of formal response criteria was difficult. Pathology review was not carried out for this study; however, most patients in the Dutch cohort and many patients treated at other participating academic centres would have had pathology review as part of routine care. In patients for whom specific histological features were recorded, dense lymphocytic infiltrate and the presence of lympho-epithelial lesions were noted in 39 of 40 (98%) and 31 of 40 (76%) patients, respectively, in keeping with the diagnosis of GMZL (data not shown). Not all patients in this series had complete documentation of gastroscopic follow-up. However, a subset analysis censoring for the date of last gastroscopy demonstrated 5-and 10-year FFTF rates comparable with that of the entire population, suggesting that the excellent long-term results in this series are not simply due to incomplete assessment at follow-up. Owing to the small number of events, the results presented are considered exploratory and require confirmation in large prospective studies.
A concern regarding the use of radiotherapy for GMZL is the potential for late toxicity, especially second malignancies. Five of 15 second malignancies in our series were likely infield. It is not possible in retrospect to identify precisely which cases may have been potentially radiotherapy related, especially for lung, breast and colon, which may have been partially in-field even for the patients not receiving whole abdominal irradiation. Three second malignancies in the WAR cohort were pelvic-a region that would not have been irradiated with a more limited irradiation approach. The second malignancy rate following limited fields and low radiotherapy doses will likely be lower than the rate reported in the present series. Furthermore, as the median patient age was 63, the potential impact of late radiotherapy-induced malignancies in this population may be less than in populations with a lower median age, such as those with Hodgkin lymphoma. No late renal toxicity was recorded. Renal toxicity can largely be avoided by minimizing the target volume and by the use of modern radiotherapy techniques including four-dimensional CT, intensity-modulated and image-guided radiotherapy [34, 35] .
The optimal treatment of GMZL that persists or recurs after HPE has been much discussed [7, 15, 36, 37] . Prolonged observation may be appropriate for patients showing ongoing improvement after HPE, as attainment of CR may take 6-18 months [4, 38] . Surgery may provide long-term remissions; N, total number of patients; IFRT, involved field RT; NF, number of patients who failed prior therapy; GMZL, gastric marginal zone lymphoma; HP, HP pylori; RT, radiotherapy; WAR, whole abdominal irradiation; FFP, freedom-from progression; CTX, chemotherapy; PD, progressive disease; SD, stable disease; PR, partial response. however, the multi-focal nature of GMZL necessitates total gastrectomy with its attendant short-and long-term morbidity [22, 23, 36, 37, [39] [40] [41] Although both chemotherapy and monoclonal antibody therapy induce responses in GMZL, their durability is unclear and cure is not anticipated to be achieved routinely [42] [43] [44] [45] [46] . Radiotherapy is very effective in the management of localized MZL and is currently widely used for patients with GMZL who fail or are unsuitable for HPE [12, 41, [47] [48] [49] . A study comparing treatment outcomes between chemotherapy, surgery or combined treatment in localized GMZL found no statistically significant survival difference between the various treatment modalities [15] . However, given the indolent natural history of this condition, and the potential for salvage therapies, a very large series with the long-term follow-up would be needed to demonstrate meaningful differences in OS according to treatment type. A prospective randomized trial comparing surgery, chemotherapy and whole abdominal radiotherapy for GMZL suggested that chemotherapy was the most effective therapy [33] . However, in this study both radiotherapy and surgery were associated with the unexpectedly high failure rates of about 50%, and relapses after whole abdominal radiotherapy were common in abdominal sites. These surprising findings lead to some uncertainty on the generalizability of these results. The uncertainties surrounding the choice of therapy following failure of HPE are underscored by a survey of opinion reported by De Jong et al., who reported some time ago that the preferred treatment varied according to region and across specialty disciplines [7] . Our data suggest that radiotherapy is an effective treatment of patients with localized GMZL, even after failure of prior HPE, surgery or chemotherapy, with the majority of patients continuing to be free of disease beyond 10 years following radiotherapy. Our data, in conjunction with previous reports, suggest that radiotherapy to the entire stomach and perigastric lymph nodes has a low longterm toxicity profile, and is likely to be curative in the majority of treated patients [9, 14] . In light of these consistent findings, there appears to be no role for whole abdominal radiotherapy in the routine management of GMZL. Thirty Gray appeared to be as effective as higher doses, and reports of the efficacy of 24 Gy for orbital MZL raise the possibility that such doses may be effective in MALT lymphoma at other sites, although this hypothesis would need to be tested in prospective clinical trials [50, 51] . Although our data would suggest caution in the use of radiotherapy alone in the presence of a large-cell component or exophytic growth pattern, and possibly gastric wall thickening, the potential impact of these risk factors requires confirmation in prospective clinical studies.
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